Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies

Biotechnology Advances

Volumn 37, Issue 1, 2019, Pages 177-192

  Pang, Zheng ^a   Raudonis, Renee ^a   Glick, Bernard R ^b   Lin, Tong Jun ^a,c   Cheng, Zhenyu ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

^c IWK HEALTH CENTRE   (Canada)

Author keywords

alternative therapeutics; antibiotic resistance; new antibiotics; Pseudomonas aeruginosa; resistance mechanisms

Indexed keywords

BACTERIA;

ACQUIRED RESISTANCE; ALTERNATIVE THERAPEUTICS; ANTIBIOTIC RESISTANCE; CLINICAL PRACTICES; MEDIATED RESISTANCES; PSEUDOMONAS AERUGINOSA; RESISTANCE MECHANISMS; THERAPEUTIC STRATEGY;

ANTIBIOTICS;

ANTIBIOTIC RESISTANCE; ANTIBIOTICS; BACTERIAL DISEASE; BACTERIUM; DISEASE RESISTANCE; DISEASE TREATMENT; INFECTIOUS DISEASE; MORBIDITY; MORTALITY; PATHOGEN;

PSEUDOMONAS AERUGINOSA;

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BIOFILM; CYSTIC FIBROSIS; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIOLOGY; PATHOGENICITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; BIOFILMS; CYSTIC FIBROSIS; DRUG RESISTANCE, MICROBIAL; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 85057518466     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2018.11.013     Document Type: Review

References (276)

1. Aggen, J.B., Armstrong, E.S., Goldblum, A.A., Dozzo, P., Linsell, M.S., et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 54 (2010), 4636–4642.
2. Aldred, K.J., Kerns, R.J., Osheroff, N., Mechanism of quinolone action and resistance. Biochemistry 53 (2014), 1565–1574.
3. Anderl, J.N., Franklin, M.J., Stewart, P.S., Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 44 (2000), 1818–1824.
4. Aoki, W., Ueda, M., Characterization of antimicrobial peptides toward the development of novel antibiotics. Pharmaceuticals (Basel) 6 (2013), 1055–1081.
5. Arber, W., Horizontal gene transfer among bacteria and its role in biological evolution. Life (Basel) 4 (2014), 217–224.
6. Askoura, M., Mottawea, W., Abujamel, T., Taher, I., Efflux pump inhibitors (EPIs) as new antimicrobial agents against Pseudomonas aeruginosa. Libyan J Med, 6, 2011.
7. Bala, A., Kumar, R., Harjai, K., Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections. J Med Microbiol 60 (2011), 300–306.
8. Balaban, N.Q., Gerdes, K., Lewis, K., McKinney, J.D., A problem of persistence: still more questions than answers?. Nat Rev Microbiol 11 (2013), 587–591.
9. Barbier, F., Andremont, A., Wolff, M., Bouadma, L., Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 19 (2013), 216–228.
10. Baum, E.Z., Crespo-Carbone, S.M., Morrow, B.J., Davies, T.A., Foleno, B.D., et al. Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53 (2009), 2785–2790.
11. Bell, A., Bains, M., Hancock, R.E., Pseudomonas aeruginosa outer membrane protein OprH: expression from the cloned gene and function in EDTA and gentamicin resistance. J Bacteriol 173 (1991), 6657–6664.
12. Bellido, F., Martin, N.L., Siehnel, R.J., Hancock, R.E., Reevaluation, using intact cells, of the exclusion limit and role of porin OprF in Pseudomonas aeruginosa outer membrane permeability. J Bacteriol 174 (1992), 5196–5203.
13. Berrazeg, M., Jeannot, K., Ntsogo Enguene, V.Y., Broutin, I., Loeffert, S., et al. Mutations in beta-Lactamase AmpC increase resistance of pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins. Antimicrob Agents Chemother 59 (2015), 6248–6255.
14. Blair, J.M., Webber, M.A., Baylay, A.J., Ogbolu, D.O., Piddock, L.J., Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 13 (2015), 42–51.
15. Boll, M., Radziejewska-Lebrecht, J., Warth, C., Krajewska-Pietrasik, D., Mayer, H., 4-Amino-4-deoxy-L-arabinose in LPS of enterobacterial R-mutants and its possible role for their polymyxin reactivity. FEMS Immunol Med Microbiol 8 (1994), 329–341.
16. Bonomo, R.A., Szabo, D., Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 43:Suppl. 2 (2006), S49–S56.
17. Bouffartigues, E., Moscoso, J.A., Duchesne, R., Rosay, T., Fito-Boncompte, L., et al. The absence of the Pseudomonas aeruginosa OprF protein leads to increased biofilm formation through variation in c-di-GMP level. Front Microbiol, 6, 2015, 630.
18. Braz, V.S., Furlan, J.P., Fernandes, A.F., Stehling, E.G., Mutations in NalC induce MexAB-OprM overexpression resulting in high level of aztreonam resistance in environmental isolates of Pseudomonas aeruginosa. FEMS Microbiol Lett, 363, 2016.
19. Breidenstein, E.B., de la Fuente-Nunez, C., Hancock, R.E., Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19 (2011), 419–426.
20. Brown, A.N., Smith, K., Samuels, T.A., Lu, J., Obare, S.O., Scott, M.E., Nanoparticles functionalized with ampicillin destroy multiple-antibiotic-resistant isolates of Pseudomonas aeruginosa and Enterobacter aerogenes and methicillin-resistant Staphylococcus aureus. Appl Environ Microbiol 78 (2012), 2768–2774.
21. Bruchmann, S., Dotsch, A., Nouri, B., Chaberny, I.F., Haussler, S., Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance. Antimicrob Agents Chemother 57 (2013), 1361–1368.
22. Bullen, J.J., Rogers, H.J., Griffiths, E., Role of iron in bacterial infection. Curr Top Microbiol Immunol 80 (1978), 1–35.
23. Bush, K., Jacoby, G.A., Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 54 (2010), 969–976.
24. Cabot, G., Ocampo-Sosa, A.A., Tubau, F., Macia, M.D., Rodriguez, C., et al. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 55 (2011), 1906–1911.
25. Cabot, G., Zamorano, L., Moya, B., Juan, C., Navas, A., et al. Evolution of Pseudomonas aeruginosa Antimicrobial resistance and fitness under low and high mutation rates. Antimicrob Agents Chemother 60 (2016), 1767–1778.
26. Cady, K.C., Bondy-Denomy, J., Heussler, G.E., Davidson, A.R., O'Toole, G.A., The CRISPR/Cas adaptive immune system of Pseudomonas aeruginosa mediates resistance to naturally occurring and engineered phages. J Bacteriol 194 (2012), 5728–5738.
27. Cady, K.C., White, A.S., Hammond, J.H., Abendroth, M.D., Karthikeyan, R.S., et al. Prevalence, conservation and functional analysis of Yersinia and Escherichia CRISPR regions in clinical Pseudomonas aeruginosa isolates. Microbiology 157 (2011), 430–437.
28. Carnoy, C., Scharfman, A., Van Brussel, E., Lamblin, G., Ramphal, R., Roussel, P., Pseudomonas aeruginosa outer membrane adhesins for human respiratory mucus glycoproteins. Infect Immun 62 (1994), 1896–1900.
29. Castanheira, M., Jones, R.N., Livermore, D.M., Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis 63 (2009), 426–433.
30. Castanheira, M., Toleman, M.A., Jones, R.N., Schmidt, F.J., Walsh, T.R., Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase. Antimicrob Agents Chemother 48 (2004), 4654–4661.
31. Cavalcanti, F.L., Mirones, C.R., Paucar, E.R., Montes, L.A., Leal-Balbino, T.C., et al. Mutational and acquired carbapenem resistance mechanisms in multidrug resistant Pseudomonas aeruginosa clinical isolates from Recife, Brazil. Mem Inst Oswaldo Cruz 110 (2015), 1003–1009.
32. Chastre, J., Wunderink, R., Prokocimer, P., Lee, M., Kaniga, K., Friedland, I., Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 36 (2008), 1089–1096.
33. Chatterjee, M., Anju, C.P., Biswas, L., Anil Kumar, V., Gopi Mohan, C., Biswas, R., Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options. Int J Med Microbiol 306 (2016), 48–58.
34. Chemani, C., Imberty, A., de Bentzmann, S., Pierre, M., Wimmerova, M., et al. Role of LecA and LecB lectins in Pseudomonas aeruginosa-induced lung injury and effect of carbohydrate ligands. Infect Immun 77 (2009), 2065–2075.
35. Chen, J., Su, Z., Liu, Y., Wang, S., Dai, X., et al. Identification and characterization of class 1 integrons among Pseudomonas aeruginosa isolates from patients in Zhenjiang, China. Int J Infect Dis 13 (2009), 717–721.
36. Chitambar, C.R., Medical applications and toxicities of gallium compounds. Int J Environ Res Public Health 7 (2010), 2337–2361.
37. Christiaen, S.E., Matthijs, N., Zhang, X.H., Nelis, H.J., Bossier, P., Coenye, T., Bacteria that inhibit quorum sensing decrease biofilm formation and virulence in Pseudomonas aeruginosa PAO1. Pathog Dis 70 (2014), 271–279.
38. Chung, P.Y., Khanum, R., Antimicrobial peptides as potential anti-biofilm agents against multidrug-resistant bacteria. J Microbiol Immunol Infect 50 (2017), 405–410.
39. Cigana, C., Bernardini, F., Facchini, M., Alcala-Franco, B., Riva, C., et al. Efficacy of the Novel Antibiotic POL7001 in Preclinical Models of Pseudomonas aeruginosa Pneumonia. Antimicrob Agents Chemother 60 (2016), 4991–5000.
40. Citorik, R.J., Mimee, M., Lu, T.K., Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol 32 (2014), 1141–1145.
41. Clokie, M.R., Millard, A.D., Letarov, A.V., Heaphy, S., Phages in nature. Bacteriophage 1 (2011), 31–45.
42. Cornelis, P., Dingemans, J., Pseudomonas aeruginosa adapts its iron uptake strategies in function of the type of infections. Front Cell Infect Microbiol, 3, 2013, 75.
43. Cox, G., Ejim, L., Stogios, P.J., Koteva, K., Bordeleau, E., et al. Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes. 2018 ACS Infect Dis.
44. Das, T., Sehar, S., Manefield, M., The roles of extracellular DNA in the structural integrity of extracellular polymeric substance and bacterial biofilm development. Environ Microbiol Rep 5 (2013), 778–786.
45. Das, T., Sharma, P.K., Busscher, H.J., van der Mei, H.C., Krom, B.P., Role of extracellular DNA in initial bacterial adhesion and surface aggregation. Appl Environ Microbiol 76 (2010), 3405–3408.
46. Daury, L., Orange, F., Taveau, J.C., Verchere, A., Monlezun, L., et al. Tripartite assembly of RND multidrug efflux pumps. Nat Commun, 7, 2016, 10731.
47. Davies, J.C., Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence. Paediatr Respir Rev 3 (2002), 128–134.
48. Davies, J.C., Alton, E.W., Bush, A., Cystic fibrosis. BMJ 335 (2007), 1255–1259.
49. Delcour, A.H., Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta 1794 (2009), 808–816.
50. van Delden, C., Kohler, T., Brunner-Ferber, F., Francois, B., Carlet, J., Pechere, J.C., Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med 38 (2012), 1118–1125.
51. DeLeon, K., Balldin, F., Watters, C., Hamood, A., Griswold, J., et al. Gallium maltolate treatment eradicates Pseudomonas aeruginosa infection in thermally injured mice. Antimicrob Agents Chemother 53 (2009), 1331–1337.
52. Diggle, S.P., Stacey, R.E., Dodd, C., Camara, M., Williams, P., Winzer, K., The galactophilic lectin, LecA, contributes to biofilm development in Pseudomonas aeruginosa. Environ Microbiol 8 (2006), 1095–1104.
53. Donlan, R.M., Biofilms: microbial life on surfaces. Emerg Infect Dis 8 (2002), 881–890.
54. Doring, G., Meisner, C., Stern, M., Flagella Vaccine Trial Study G, A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci U S A 104 (2007), 11020–11025.
55. Doring, G., Pier, G.B., Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 26 (2008), 1011–1024.
56. Dorr, T., Vulic, M., Lewis, K., Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol, 8, 2010, e1000317.
57. Dosler, S., Karaaslan, E., Inhibition and destruction of Pseudomonas aeruginosa biofilms by antibiotics and antimicrobial peptides. Peptides 62 (2014), 32–37.
58. Drawz, S.M., Bonomo, R.A., Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 23 (2010), 160–201.
59. Dreier, J., Ruggerone, P., Interaction of antibacterial compounds with RND e ffl ux pumps in Pseudomonas aeruginosa. Front Microbiol, 6, 2015, 660.
60. Drenkard, E., Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes Infect 5 (2003), 1213–1219.
61. Drenkard, E., Ausubel, F.M., Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416 (2002), 740–743.
62. Dupont, P., Hocquet, D., Jeannot, K., Chavanet, P., Plesiat, P., Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa. J Antimicrob Chemother 55 (2005), 518–522.
63. El Solh, A.A., Alhajhusain, A., Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother 64 (2009), 229–238.
64. El'Garch, F., Jeannot, K., Hocquet, D., Llanes-Barakat, C., Plesiat, P., Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 51 (2007), 1016–1021.
65. Elsaesser, A., Howard, C.V., Toxicology of nanoparticles. Adv Drug Deliv Rev 64 (2012), 129–137.
66. El-Shaer, S., Shaaban, M., Barwa, R., Hassan, R., Control of quorum sensing and virulence factors of Pseudomonas aeruginosa using phenylalanine arginyl beta-naphthylamide. J Med Microbiol 65 (2016), 1194–1204.
67. Fang, Z.L., Zhang, L.Y., Huang, Y.M., Qing, Y., Cao, K.Y., et al. OprD mutations and inactivation in imipenem-resistant Pseudomonas aeruginosa isolates from China. Infect Genet Evol 21 (2014), 124–128.
68. Fernandez, L., Hancock, R.E., Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev 25 (2012), 661–681.
69. Fong, S.A., Drilling, A., Morales, S., Cornet, M.E., Woodworth, B.A., et al. Activity of Bacteriophages in Removing biofilms of Pseudomonas aeruginosa Isolates from Chronic Rhinosinusitis patients. Front Cell Infect Microbiol, 7, 2017, 418.
70. Fu, W., Forster, T., Mayer, O., Curtin, J.J., Lehman, S.M., Donlan, R.M., Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother 54 (2010), 397–404.
71. Gellatly, S.L., Hancock, R.E., Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis 67 (2013), 159–173.
72. Ghafoor, A., Hay, I.D., Rehm, B.H., Role of exopolysaccharides in Pseudomonas aeruginosa biofilm formation and architecture. Appl Environ Microbiol 77 (2011), 5238–5246.
73. Giacometti, A., Cirioni, O., Barchiesi, F., Fortuna, M., Scalise, G., In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. J Antimicrob Chemother 44 (1999), 641–645.
74. Gillis, R.J., White, K.G., Choi, K.H., Wagner, V.E., Schweizer, H.P., Iglewski, B.H., Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 49 (2005), 3858–3867.
75. Glessner, A., Smith, R.S., Iglewski, B.H., Robinson, J.B., Roles of Pseudomonas aeruginosa las and rhl quorum-sensing systems in control of twitching motility. J Bacteriol 181 (1999), 1623–1629.
76. Gokalsin, B., Aksoydan, B., Erman, B., Sesal, N.C., Reducing virulence and biofilm of Pseudomonas aeruginosa by potential Quorum Sensing Inhibitor Carotenoid: Zeaxanthin. Microb Ecol 74 (2017), 466–473.
77. Goodman, A.L., Kulasekara, B., Rietsch, A., Boyd, D., Smith, R.S., Lory, S., A signaling network reciprocally regulates genes associated with acute infection and chronic persistence in Pseudomonas aeruginosa. Dev Cell 7 (2004), 745–754.
78. Gordon, Y.J., Romanowski, E.G., McDermott, A.M., A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr Eye Res 30 (2005), 505–515.
79. Grassi, L., Di Luca, M., Maisetta, G., Rinaldi, A.C., Esin, S., et al. Generation of persister cells of Pseudomonas aeruginosa and Staphylococcus aureus by chemical treatment and evaluation of their susceptibility to membrane-targeting agents. Front Microbiol, 8, 2017, 1917.
80. Grassi, L., Maisetta, G., Esin, S., Batoni, G., Combination strategies to enhance the efficacy of antimicrobial peptides against bacterial biofilms. Front Microbiol, 8, 2017, 2409.
81. Greer, N.D., Doripenem (Doribax): the newest addition to the carbapenems. Proc (Bayl Univ Med Cent) 21 (2008), 337–341.
82. Grimwood, K., Kyd, J.M., Owen, S.J., Massa, H.M., Cripps, A.W., Vaccination against respiratory Pseudomonas aeruginosa infection. Hum Vaccin Immunother 11 (2015), 14–20.
83. Grishin, A.V., Krivozubov, M.S., Karyagina, A.S., Gintsburg, A.L., Pseudomonas Aeruginosa Lectins as targets for novel antibacterials. Acta Naturae 7 (2015), 29–41.
84. Guenard, S., Muller, C., Monlezun, L., Benas, P., Broutin, I., et al. Multiple mutations lead to MexXY-OprM-dependent aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 58 (2014), 221–228.
85. Gwinn, M.R., Vallyathan, V., Nanoparticles: health effects–pros and cons. Environ Health Perspect 114 (2006), 1818–1825.
86. Ha, D.G., O'Toole, G.A., c-di-GMP and its effects on biofilm formation and dispersion: a Pseudomonas Aeruginosa review. Microbiol Spectr, 3, 2015 MB-0003-2014.
87. Hachler, H., Santanam, P., Kayser, F.H., Sequence and characterization of a novel chromosomal aminoglycoside phosphotransferase gene, aph (3’)-IIb, in Pseudomonas aeruginosa. Antimicrob Agents Chemother 40 (1996), 1254–1256.
88. Hagens, S., Habel, A., von Ahsen, U., von Gabain, A., Blasi, U., Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 48 (2004), 3817–3822.
89. Hainrichson, M., Yaniv, O., Cherniavsky, M., Nudelman, I., Shallom-Shezifi, D., et al. Overexpression and initial characterization of the chromosomal aminoglycoside 3’-O-phosphotransferase APH(3’)-IIb from Pseudomonas aeruginosa. Antimicrob Agents Chemother 51 (2007), 774–776.
90. Hall, R.M., Collis, C.M., Mobile gene cassettes and integrons: capture and spread of genes by site-specific recombination. Mol Microbiol 15 (1995), 593–600.
91. Hancock, R.E., Brinkman, F.S., Function of pseudomonas porins in uptake and efflux. Annu Rev Microbiol 56 (2002), 17–38.
92. Hancock, R.E., Haney, E.F., Gill, E.E., The immunology of host defence peptides: beyond antimicrobial activity. Nat Rev Immunol 16 (2016), 321–334.
93. Hancock, R.E., Speert, D.P., Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Updat 3 (2000), 247–255.
94. Hartl, D., Gaggar, A., Bruscia, E., Hector, A., Marcos, V., et al. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros 11 (2012), 363–382.
95. Harvey, H., Bondy-Denomy, J., Marquis, H., Sztanko, K.M., Davidson, A.R., Burrows, L.L., Pseudomonas aeruginosa defends against phages through type IV pilus glycosylation. Nat Microbiol 3 (2018), 47–52.
96. Hengge, R., Principles of c-di-GMP signalling in bacteria. Nat Rev Microbiol 7 (2009), 263–273.
97. Henrichfreise, B., Wiegand, I., Pfister, W., Wiedemann, B., Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother 51 (2007), 4062–4070.
98. Hentzer, M., Riedel, K., Rasmussen, T.B., Heydorn, A., Andersen, J.B., et al. Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 148 (2002), 87–102.
99. Hilas, O., Ezzo, D.C., Jodlowski, T.Z., Doripenem (doribax), a new carbapenem antibacterial agent. P T 33 (2008), 134–180.
100. Hirsch, E.B., Tam, V.H., Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res 10 (2010), 441–451.
101. Hirt, H., Gorr, S.U., Antimicrobial peptide GL13K is effective in reducing biofilms of Pseudomonas aeruginosa. Antimicrob Agents Chemother 57 (2013), 4903–4910.
102. Hocquet, D., Nordmann, P., El Garch, F., Cabanne, L., Plesiat, P., Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 50 (2006), 1347–1351.
103. Hocquet, D., Vogne, C., El Garch, F., Vejux, A., Gotoh, N., et al. MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 47 (2003), 1371–1375.
104. Hong, D.J., Bae, I.K., Jang, I.H., Jeong, S.H., Kang, H.K., Lee, K., Epidemiology and characteristics of Metallo-beta-Lactamase-producing Pseudomonas aeruginosa. Infect Chemother 47 (2015), 81–97.
105. Hoyland-Kroghsbo, N.M., Paczkowski, J., Mukherjee, S., Broniewski, J., Westra, E., et al. Quorum sensing controls the Pseudomonas aeruginosa CRISPR-Cas adaptive immune system. Proc Natl Acad Sci U S A 114 (2017), 131–135.
106. Hurley, M.N., Camara, M., Smyth, A.R., Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur Respir J 40 (2012), 1014–1023.
107. Imperi, F., Leoni, L., Visca, P., Antivirulence activity of azithromycin in Pseudomonas aeruginosa. Front Microbiol, 5, 2014, 178.
108. Inoue, K., Takano, H., Yanagisawa, R., Hirano, S., Sakurai, M., et al. Effects of airway exposure to nanoparticles on lung inflammation induced by bacterial endotoxin in mice. Environ Health Perspect 114 (2006), 1325–1330.
109. Ishida, T., Ikeda, T., Takiguchi, N., Kuroda, A., Ohtake, H., Kato, J., Inhibition of quorum sensing in Pseudomonas aeruginosa by N-acyl cyclopentylamides. Appl Environ Microbiol 73 (2007), 3183–3188.
110. Istanbullu, O., Babauta, J., Duc Nguyen, H., Beyenal, H., Electrochemical biofilm control: mechanism of action. Biofouling 28 (2012), 769–778.
111. Jacoby, G.A., Blaser, M.J., Santanam, P., Hachler, H., Kayser, F.H., et al. Appearance of amikacin and tobramycin resistance due to 4’-aminoglycoside nucleotidyltransferase [ANT(4’)-II] in gram-negative pathogens. Antimicrob Agents Chemother 34 (1990), 2381–2386.
112. Jeevanandam, J., Barhoum, A., Chan, Y.S., Dufresne, A., Danquah, M.K., Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol 9 (2018), 1050–1074.
113. Johansson, E.M., Crusz, S.A., Kolomiets, E., Buts, L., Kadam, R.U., et al. Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LecB. Chem Biol 15 (2008), 1249–1257.
114. Juan, C., Macia, M.D., Gutierrez, O., Vidal, C., Perez, J.L., Oliver, A., Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 49 (2005), 4733–4738.
115. Jyot, J., Sonawane, A., Wu, W., Ramphal, R., Genetic mechanisms involved in the repression of flagellar assembly by Pseudomonas aeruginosa in human mucus. Mol Microbiol 63 (2007), 1026–1038.
116. Kadam, R.U., Bergmann, M., Hurley, M., Garg, D., Cacciarini, M., et al. A glycopeptide dendrimer inhibitor of the galactose-specific lectin LecA and of Pseudomonas aeruginosa biofilms. Angew Chem Int Ed Engl 50 (2011), 10631–10635.
117. Kalia, V.C., Quorum sensing inhibitors: an overview. Biotechnol Adv 31 (2013), 224–245.
118. Kaneko, Y., Thoendel, M., Olakanmi, O., Britigan, B.E., Singh, P.K., The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J Clin Invest 117 (2007), 877–888.
119. Kang, D., Turner, K.E., Kirienko, N.V., PqsA promotes Pyoverdine production via biofilm formation. Pathogens, 7, 2017.
120. Karaiskos, I., Souli, M., Giamarellou, H., Plazomicin: an investigational therapy for the treatment of urinary tract infections. Expert Opin Investig Drugs 24 (2015), 1501–1511.
121. Kaspy, I., Rotem, E., Weiss, N., Ronin, I., Balaban, N.Q., Glaser, G., HipA-mediated antibiotic persistence via phosphorylation of the glutamyl-tRNA-synthetase. Nat Commun, 4, 2013, 3001.
122. Khajuria, A., Praharaj, A.K., Kumar, M., Grover, N., Emergence of NDM – 1 in the clinical isolates of Pseudomonas aeruginosa in India. J Clin Diagn Res 7 (2013), 1328–1331.
123. Khosravi, A.D., Motahar, M., Abbasi, Montazeri E., The frequency of class1 and 2 integrons in Pseudomonas aeruginosa strains isolated from burn patients in a burn center of Ahvaz, Iran. PLoS One, 12, 2017, e0183061.
124. de Kievit, T.R., Iglewski, B.H., Bacterial quorum sensing in pathogenic relationships. Infect Immun 68 (2000), 4839–4849.
125. Kim, Y., Wood, T.K., Toxins Hha and CspD and small RNA regulator Hfq are involved in persister cell formation through MqsR in Escherichia coli. Biochem Biophys Res Commun 391 (2010), 209–213.
126. Kitao, T., Lepine, F., Babloudi, S., Walte, F., Steinbacher, S., et al. Molecular insights into function and competitive inhibition of Pseudomonas aeruginosa multiple virulence factor regulator. MBio, 9, 2018.
127. Klockgether, J., Cramer, N., Wiehlmann, L., Davenport, C.F., Tummler, B., Pseudomonas aeruginosa Genomic Structure and Diversity. Front Microbiol, 2, 2011, 150.
128. Krachler, A.M., Orth, K., Targeting the bacteria-host interface: strategies in anti-adhesion therapy. Virulence 4 (2013), 284–294.
129. Kwon, E.J., Skalak, M., Bertucci, A., Braun, G., Ricci, F., et al. Porous silicon nanoparticle delivery of Tandem peptide anti-infectives for the treatment of Pseudomonas aeruginosa lung infections. Adv Mater, 29, 2017.
130. Labrie, S.J., Samson, J.E., Moineau, S., Bacteriophage resistance mechanisms. Nat Rev Microbiol 8 (2010), 317–327.
131. Lambert, P.A., Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J R Soc Med 95:Suppl. 41 (2002), 22–26.
132. Lamers, R.P., Cavallari, J.F., Burrows, L.L., The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAbetaN) permeabilizes the outer membrane of gram-negative bacteria. PLoS One, 8, 2013, e60666.
133. Lavoie, E.G., Wangdi, T., Kazmierczak, B.I., Innate immune responses to Pseudomonas aeruginosa infection. Microbes Infect 13 (2011), 1133–1145.
134. Lee, J., Zhang, L., The hierarchy quorum sensing network in Pseudomonas aeruginosa. Protein Cell 6 (2015), 26–41.
135. Lerrer, B., Zinger-Yosovich, K.D., Avrahami, B., Gilboa-Garber, N., Honey and royal jelly, like human milk, abrogate lectin-dependent infection-preceding Pseudomonas aeruginosa adhesion. ISME J 1 (2007), 149–155.
136. Lewis, K., Persister cells. Annu Rev Microbiol 64 (2010), 357–372.
137. Li, H., Luo, Y.F., Williams, B.J., Blackwell, T.S., Xie, C.M., Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol 302 (2012), 63–68.
138. Li, X.Z., Nikaido, H., Efflux-mediated drug resistance in bacteria: an update. Drugs 69 (2009), 1555–1623.
139. Lister, P.D., Wolter, D.J., Hanson, N.D., Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22 (2009), 582–610.
140. Llanes, C., Hocquet, D., Vogne, C., Benali-Baitich, D., Neuwirth, C., Plesiat, P., Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrob Agents Chemother 48 (2004), 1797–1802.
141. Llanes, C., Kohler, T., Patry, I., Dehecq, B., van Delden, C., Plesiat, P., Role of the MexEF-OprN efflux system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin. Antimicrob Agents Chemother 55 (2011), 5676–5684.
142. Lu, T.K., Collins, J.J., Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A 104 (2007), 11197–11202.
143. Lu, T.K., Collins, J.J., Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci U S A 106 (2009), 4629–4634.
144. Luyt, C.E., Aubry, A., Lu, Q., Micaelo, M., Brechot, N., et al. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother 58 (2014), 1372–1380.
145. Ly-Chatain, M.H., The factors affecting effectiveness of treatment in phages therapy. Front Microbiol, 5, 2014, 51.
146. Lyczak, J.B., Cannon, C.L., Pier, G.B., Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15 (2002), 194–222.
147. Ma, L., Terwilliger, A., Maresso, A.W., Iron and zinc exploitation during bacterial pathogenesis. Metallomics 7 (2015), 1541–1554.
148. Macfarlane, E.L., Kwasnicka, A., Ochs, M.M., Hancock, R.E., PhoP-PhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer-membrane protein OprH and polymyxin B resistance. Mol Microbiol 34 (1999), 305–316.
149. Mah, T.F., Pitts, B., Pellock, B., Walker, G.C., Stewart, P.S., O'Toole, G.A., A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426 (2003), 306–310.
150. Maisonneuve, E., Gerdes, K., Molecular mechanisms underlying bacterial persisters. Cell 157 (2014), 539–548.
151. Mandsberg, L.F., Ciofu, O., Kirkby, N., Christiansen, L.E., Poulsen, H.E., Hoiby, N., Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob Agents Chemother 53 (2009), 2483–2491.
152. Marraffini, L.A., Sontheimer, E.J., CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. Nat Rev Genet 11 (2010), 181–190.
153. Masuda, N., Sakagawa, E., Ohya, S., Gotoh, N., Tsujimoto, H., Nishino, T., Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 44 (2000), 3322–3327.
154. Maura, D., Rahme, L.G., Pharmacological inhibition of the Pseudomonas aeruginosa MvfR Quorum-sensing system interferes with biofilm formation and potentiates antibiotic-mediated biofilm disruption. Antimicrob Agents Chemother, 2017, 61.
155. Merabishvili, M., Pirnay, J.P., Verbeken, G., Chanishvili, N., Tediashvili, M., et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One, 4, 2009, e4944.
156. Miller, M.B., Bassler, B.L., Quorum sensing in bacteria. Annu Rev Microbiol 55 (2001), 165–199.
157. Miller, A.K., Brannon, M.K., Stevens, L., Johansen, H.K., Selgrade, S.E., et al. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother 55 (2011), 5761–5769.
158. Miller, M.R., Raftis, J.B., Langrish, J.P., McLean, S.G., Samutrtai, P., et al. Inhaled nanoparticles accumulate at sites of vascular disease. ACS Nano 11 (2017), 4542–4552.
159. Minandri, F., Bonchi, C., Frangipani, E., Imperi, F., Visca, P., Promises and failures of gallium as an antibacterial agent. Future Microbiol 9 (2014), 379–397.
160. Mingeot-Leclercq, M.P., Glupczynski, Y., Tulkens, P.M., Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 43 (1999), 727–737.
161. Mlynarcik, P., Kolar, M., Starvation- and antibiotics-induced formation of persister cells in Pseudomonas aeruginosa. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 161 (2017), 58–67.
162. Moker, N., Dean, C.R., Tao, J., Pseudomonas aeruginosa increases formation of multidrug-tolerant persister cells in response to quorum-sensing signaling molecules. J Bacteriol 192 (2010), 1946–1955.
163. Moreau-Marquis, S., O'Toole, G.A., Stanton, B.A., Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol 41 (2009), 305–313.
164. Morello, E., Saussereau, E., Maura, D., Huerre, M., Touqui, L., Debarbieux, L., Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One, 6, 2011, e16963.
165. Moskowitz, S.M., Ernst, R.K., Miller, S.I., PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol 186 (2004), 575–579.
166. Moya, B., Beceiro, A., Cabot, G., Juan, C., Zamorano, L., et al. Pan-beta-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother 56 (2012), 4771–4778.
167. Mulcahy, L.R., Burns, J.L., Lory, S., Lewis, K., Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol 192 (2010), 6191–6199.
168. Munita, J.M., Arias, C.A., Mechanisms of antibiotic resistance. Microbiol Spectr, 4, 2016.
169. Murphy, T.F., Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr Opin Pulm Med 15 (2009), 138–142.
170. Nguyen, D., Joshi-Datar, A., Lepine, F., Bauerle, E., Olakanmi, O., et al. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science 334 (2011), 982–986.
171. Nikaido, H., Nikaido, K., Harayama, S., Identification and characterization of porins in Pseudomonas aeruginosa. J Biol Chem 266 (1991), 770–779.
172. Nikokar, I., Tishayar, A., Flakiyan, Z., Alijani, K., Rehana-Banisaeed, S., et al. Antibiotic resistance and frequency of class 1 integrons among Pseudomonas aeruginosa, isolated from burn patients in Guilan, Iran. Iran J Microbiol 5 (2013), 36–41.
173. Nilsson, C.L., Lectins: proteins that interpret the sugar code. Anal Chem, 75, 2003 (348A-53A).
174. Ochs, M.M., Bains, M., Hancock, R.E., Role of putative loops 2 and 3 in imipenem passage through the specific porin OprD of Pseudomonas aeruginosa. Antimicrob Agents Chemother 44 (2000), 1983–1985.
175. Odumosu, B.T., Adeniyi, B.A., Chandra, R., Analysis of integrons and associated gene cassettes in clinical isolates of multidrug resistant Pseudomonas aeruginosa from Southwest Nigeria. Ann Clin Microbiol Antimicrob, 12, 2013, 29.
176. Ofek, I., Hasty, D.L., Sharon, N., Anti-adhesion therapy of bacterial diseases: prospects and problems. FEMS Immunol Med Microbiol 38 (2003), 181–191.
177. Okamoto, K., Gotoh, N., Nishino, T., Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa. Antimicrob Agents Chemother 46 (2002), 2696–2699.
178. O'May, C.Y., Sanderson, K., Roddam, L.F., Kirov, S.M., Reid, D.W., Iron-binding compounds impair Pseudomonas aeruginosa biofilm formation, especially under anaerobic conditions. J Med Microbiol 58 (2009), 765–773.
179. Ormala, A.M., Jalasvuori, M., Phage therapy: Should bacterial resistance to phages be a concern, even in the long run?. Bacteriophage, 3, 2013, e24219.
180. O'Toole, G.A., Kolter, R., Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 30 (1998), 295–304.
181. Owusu-Anim, D., Kwon, D.H., Differential role of two-component regulatory systems (phoPQ and pmrAB) in Polymyxin B susceptibility of Pseudomonas aeruginosa. Adv Microbiol, 2, 2012.
182. Paczkowski, J.E., Mukherjee, S., McCready, A.R., Cong, J.P., Aquino, C.J., et al. Flavonoids suppress Pseudomonas aeruginosa virulence through Allosteric inhibition of Quorum-sensing receptors. J Biol Chem 292 (2017), 4064–4076.
183. Pankuch, G.A., Lin, G., Kubo, A., Armstrong, E.S., Appelbaum, P.C., Kosowska-Shick, K., Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa. Antimicrob Agents Chemother 55 (2011), 2463–2465.
184. Papareddy, P., Kasetty, G., Kalle, M., Bhongir, R.K., Morgelin, M., et al. NLF20: an antimicrobial peptide with therapeutic potential against invasive Pseudomonas aeruginosa infection. J Antimicrob Chemother 71 (2016), 170–180.
185. Park, S.C., Park, Y., Hahm, K.S., The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation. Int J Mol Sci 12 (2011), 5971–5992.
186. Park, S.Y., Park, H.J., Moon, S.M., Park, K.H., Chong, Y.P., et al. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia. BMC Infect Dis, 12, 2012, 308.
187. Parkins, M.D., Ceri, H., Storey, D.G., Pseudomonas aeruginosa GacA, a factor in multihost virulence, is also essential for biofilm formation. Mol Microbiol 40 (2001), 1215–1226.
188. Paterson, D.L., Bonomo, R.A., Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18 (2005), 657–686.
189. Paterson, D.L., Depestel, D.D., Doripenem. Clin Infect Dis 49 (2009), 291–298.
190. Pires, D.P., Cleto, S., Sillankorva, S., Azeredo, J., Lu, T.K., Genetically engineered phages: a review of advances over the last decade. Microbiol Mol Biol Rev 80 (2016), 523–543.
191. Pires, D.P., Vilas Boas, D., Sillankorva, S., Azeredo, J., Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol 89 (2015), 7449–7456.
192. Pletzer, D., Coleman, S.R., Hancock, R.E., Anti-biofilm peptides as a new weapon in antimicrobial warfare. Curr Opin Microbiol 33 (2016), 35–40.
193. Poirel, L., Lambert, T., Turkoglu, S., Ronco, E., Gaillard, J., Nordmann, P., Characterization of Class 1 integrons from Pseudomonas aeruginosa that contain the bla(VIM-2) carbapenem-hydrolyzing beta-lactamase gene and of two novel aminoglycoside resistance gene cassettes. Antimicrob Agents Chemother 45 (2001), 546–552.
194. Poole, K., Resistance to beta-lactam antibiotics. Cell Mol Life Sci 61 (2004), 2200–2223.
195. Poole, K., Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49 (2005), 479–487.
196. Poole, K., Pseudomonas aeruginosa: resistance to the max. Front Microbiol, 2, 2011, 65.
197. Poole, K., Gotoh, N., Tsujimoto, H., Zhao, Q., Wada, A., et al. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 21 (1996), 713–724.
198. Poonsuk, K., Tribuddharat, C., Chuanchuen, R., Simultaneous overexpression of multidrug efflux pumps in Pseudomonas aeruginosa non-cystic fibrosis clinical isolates. Can J Microbiol 60 (2014), 437–443.
199. Priebe, G.P., Goldberg, J.B., Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines 13 (2014), 507–519.
200. Pritt, B., O'Brien, L., Winn, W., Mucoid Pseudomonas in cystic fibrosis. Am J Clin Pathol 128 (2007), 32–34.
201. Queenan, A.M., Shang, W., Flamm, R., Bush, K., Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob Agents Chemother 54 (2010), 565–569.
202. Ramirez, M.S., Tolmasky, M.E., Aminoglycoside modifying enzymes. Drug Resist Updat 13 (2010), 151–171.
203. Rampioni, G., Pillai, C.R., Longo, F., Bondi, R., Baldelli, V., et al. Effect of efflux pump inhibition on Pseudomonas aeruginosa transcriptome and virulence. Sci Rep, 7, 2017, 11392.
204. Rasamiravaka, T., Labtani, Q., Duez, P., El Jaziri, M., The formation of biofilms by Pseudomonas aeruginosa: a review of the natural and synthetic compounds interfering with control mechanisms. Biomed Res Int, 2015, 2015, 759348.
205. Rasmussen, T.B., Givskov, M., Quorum sensing inhibitors: a bargain of effects. Microbiology 152 (2006), 895–904.
206. Ratjen, F., Brockhaus, F., Angyalosi, G., Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J Cyst Fibros 8 (2009), 361–369.
207. Rawat, D., Nair, D., Extended-spectrum beta-lactamases in Gram negative bacteria. J Glob Infect Dis 2 (2010), 263–274.
208. Reid, D.W., Carroll, V., O'May, C., Champion, A., Kirov, S.M., Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis. Eur Respir J 30 (2007), 286–292.
209. Reuter, K., Steinbach, A., Helms, V., Interfering with Bacterial Quorum sensing. Perspect Medicin Chem 8 (2016), 1–15.
210. Rhoads, D.D., Wolcott, R.D., Kuskowski, M.A., Wolcott, B.M., Ward, L.S., Sulakvelidze, A., Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 18:237-8 (2009), 40–43.
211. Riera, E., Cabot, G., Mulet, X., Garcia-Castillo, M., del Campo, R., et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother 66 (2011), 2022–2027.
212. Rutherford, S.T., Bassler, B.L., Bacterial quorum sensing: its role in virulence and possibilities for its control. Cold Spring Harb Perspect Med, 2, 2012.
213. Sadikot, R.T., Blackwell, T.S., Christman, J.W., Prince, A.S., Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 171 (2005), 1209–1223.
214. Sadovskaya, I., Vinogradov, E., Li, J., Hachani, A., Kowalska, K., Filloux, A., High-level antibiotic resistance in Pseudomonas aeruginosa biofilm: the ndvB gene is involved in the production of highly glycerol-phosphorylated beta-(1->3)-glucans, which bind aminoglycosides. Glycobiology 20 (2010), 895–904.
215. Saiman, L., Marshall, B.C., Mayer-Hamblett, N., Burns, J.L., Quittner, A.L., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 (2003), 1749–1756.
216. Saito, K., Yoneyama, H., Nakae, T., nalB-type mutations causing the overexpression of the MexAB-OprM efflux pump are located in the mexR gene of the Pseudomonas aeruginosa chromosome. FEMS Microbiol Lett 179 (1999), 67–72.
217. Salata, O., Applications of nanoparticles in biology and medicine. J Nanobiotechnology, 2, 2004, 3.
218. Salomoni, R., Leo, P., Montemor, A.F., Rinaldi, B.G., Rodrigues, M., Antibacterial effect of silver nanoparticles in Pseudomonas aeruginosa. Nanotechnol Sci Appl 10 (2017), 115–121.
219. Sandoval-Motta, S., Aldana, M., Adaptive resistance to antibiotics in bacteria: a systems biology perspective. Wiley Interdiscip Rev Syst Biol Med 8 (2016), 253–267.
220. Shigemura, K., Osawa, K., Kato, A., Tokimatsu, I., Arakawa, S., et al. Association of overexpression of efflux pump genes with antibiotic resistance in Pseudomonas aeruginosa strains clinically isolated from urinary tract infection patients. J Antibiot (Tokyo) 68 (2015), 568–572.
221. Silby, M.W., Winstanley, C., Godfrey, S.A., Levy, S.B., Jackson, R.W., Pseudomonas genomes: diverse and adaptable. FEMS Microbiol Rev 35 (2011), 652–680.
222. Singhai, M., Malik, A., Shahid, M., Malik, M.A., Goyal, R., A study on device-related infections with special reference to biofilm production and antibiotic resistance. J Glob Infect Dis 4 (2012), 193–198.
223. Srikumar, R., Paul, C.J., Poole, K., Influence of mutations in the mexR repressor gene on expression of the MexA-MexB-oprM multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 182 (2000), 1410–1414.
224. Srinivas, N., Jetter, P., Ueberbacher, B.J., Werneburg, M., Zerbe, K., et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327 (2010), 1010–1013.
225. Starkey, M., Lepine, F., Maura, D., Bandyopadhaya, A., Lesic, B., et al. Identification of anti-virulence compounds that disrupt quorum-sensing regulated acute and persistent pathogenicity. PLoS Pathog, 10, 2014, e1004321.
226. Stern, A., Sorek, R., The phage-host arms race: shaping the evolution of microbes. Bioessays 33 (2011), 43–51.
227. Stewart, P.S., Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 292 (2002), 107–113.
228. Stewart, P.S., Costerton, J.W., Antibiotic resistance of bacteria in biofilms. Lancet 358 (2001), 135–138.
229. Storz, M.P., Maurer, C.K., Zimmer, C., Wagner, N., Brengel, C., et al. Validation of PqsD as an anti-biofilm target in Pseudomonas aeruginosa by development of small-molecule inhibitors. J Am Chem Soc 134 (2012), 16143–16146.
230. Stover, C.K., Pham, X.Q., Erwin, A.L., Mizoguchi, S.D., Warrener, P., et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406 (2000), 959–964.
231. Subedi, D., Vijay, A.K., Willcox, M., Overview of mechanisms of antibiotic resistance in Pseudomonas aeruginosa: an ocular perspective. Clin Exp Optom 101 (2018), 162–171.
232. Sugawara, E., Nestorovich, E.M., Bezrukov, S.M., Nikaido, H., Pseudomonas aeruginosa porin OprF exists in two different conformations. J Biol Chem 281 (2006), 16220–16229.
233. Sulakvelidze, A., Alavidze, Z., Morris, J.G. Jr., Bacteriophage therapy. Antimicrob Agents Chemother 45 (2001), 649–659.
234. Sultana, S.T., Atci, E., Babauta, J.T., Falghoush, A.M., Snekvik, K.R., et al. Electrochemical scaffold generates localized, low concentration of hydrogen peroxide that inhibits bacterial pathogens and biofilms. Sci Rep, 5, 2015, 14908.
235. Sultana, S.T., Call, D.R., Beyenal, H., Eradication of Pseudomonas aeruginosa biofilms and persister cells using an electrochemical scaffold and enhanced antibiotic susceptibility. NPJ Biofilms Microbiomes, 2, 2016, 2.
236. Sun, J., Deng, Z., Yan, A., Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. Biochem Biophys Res Commun 453 (2014), 254–267.
237. Susilowati, H., Murakami, K., Yumoto, H., Amoh, T., Hirao, K., et al. Royal jelly inhibits Pseudomonas aeruginosa adherence and reduces excessive inflammatory responses in human epithelial cells. Biomed Res Int, 2017, 2017, 3191752.
238. Tacconelli, E., Magrini, N., Carmeli, Y., Harbarth, S., Kahlmeter, G., Kluytmans, J., Mendelson, M., Pulcini, C., Singh, N., Theuretzbacher, U., Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization, 2017, 1–7 (http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. Last date of access: Nov.18.2018).
239. Tateda, K., Comte, R., Pechere, J.C., Kohler, T., Yamaguchi, K., Van Delden, C., Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 45 (2001), 1930–1933.
240. Taylor, P.K., Yeung, A.T., Hancock, R.E., Antibiotic resistance in Pseudomonas aeruginosa biofilms: towards the development of novel anti-biofilm therapies. J Biotechnol 191 (2014), 121–130.
241. Tian, Z.X., Yi, X.X., Cho, A., O'Gara, F., Wang, Y.P., CpxR activates MexAB-OprM efflux pump expression and enhances antibiotic resistance in both laboratory and clinical nalB-type isolates of Pseudomonas aeruginosa. PLoS Pathog, 12, 2016, e1005932.
242. Tielker, D., Hacker, S., Loris, R., Strathmann, M., Wingender, J., et al. Pseudomonas aeruginosa lectin LecB is located in the outer membrane and is involved in biofilm formation. Microbiology 151 (2005), 1313–1323.
243. Toke, O., Antimicrobial peptides: new candidates in the fight against bacterial infections. Biopolymers 80 (2005), 717–735.
244. Traczewski, M.M., Brown, S.D., In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother 50 (2006), 819–821.
245. Unterholzner, S.J., Poppenberger, B., Rozhon, W., Toxin-antitoxin systems: biology, identification, and application. Mob Genet Elements, 3, 2013, e26219.
246. Van den Bergh, B., Fauvart, M., Michiels, J., Formation, physiology, ecology, evolution and clinical importance of bacterial persisters. FEMS Microbiol Rev 41 (2017), 219–251.
247. Vandenheuvel, D., Lavigne, R., Brussow, H., Bacteriophage therapy: advances in formulation strategies and human clinical trials. Annu Rev Virol 2 (2015), 599–618.
248. Ventola, C.L., The antibiotic resistance crisis: part 1: causes and threats. P T 40 (2015), 277–283.
249. Vieira, A., Silva, Y.J., Cunha, A., Gomes, N.C., Ackermann, H.W., Almeida, A., Phage therapy to control multidrug-resistant Pseudomonas aeruginosa skin infections: in vitro and ex vivo experiments. Eur J Clin Microbiol Infect Dis 31 (2012), 3241–3249.
250. Vincent, J.L., Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update. Future Microbiol 9 (2014), 457–463.
251. Walkty, A., Adam, H., Baxter, M., Denisuik, A., Lagace-Wiens, P., et al. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011–2012. Antimicrob Agents Chemother 58 (2014), 2554–2563.
252. Walters, M.C. 3rd, Roe, F., Bugnicourt, A., Franklin, M.J., Stewart, P.S., Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 47 (2003), 317–323.
253. Wang, L., Hu, C., Shao, L., The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int J Nanomedicine 12 (2017), 1227–1249.
254. Wang, X., Wood, T.K., Toxin-antitoxin systems influence biofilm and persister cell formation and the general stress response. Appl Environ Microbiol 77 (2011), 5577–5583.
255. Waters, E.M., Neill, D.R., Kaman, B., Sahota, J.S., Clokie, M.R.J., et al. Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax 72 (2017), 666–667.
256. Welte, W., Nestel, U., Wacker, T., Diederichs, K., Structure and function of the porin channel. Kidney Int 48 (1995), 930–940.
257. Wen, Y., Behiels, E., Devreese, B., Toxin-Antitoxin systems: their role in persistence, biofilm formation, and pathogenicity. Pathog Dis 70 (2014), 240–249.
258. Westwater, C., Kasman, L.M., Schofield, D.A., Werner, P.A., Dolan, J.W., et al. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 47 (2003), 1301–1307.
259. Wilton, M., Charron-Mazenod, L., Moore, R., Lewenza, S., Extracellular DNA Acidifies biofilms and induces Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 60 (2016), 544–553.
260. Wittebole, X., De Roock, S., Opal, S.M., A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 5 (2014), 226–235.
261. Wnorowska, U., Niemirowicz, K., Myint, M., Diamond, S.L., Wroblewska, M., et al. Bactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58. Antimicrob Agents Chemother 59 (2015), 3808–3815.
262. Wolter, D.J., Hanson, N.D., Lister, P.D., Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance. FEMS Microbiol Lett 236 (2004), 137–143.
263. Wolter, D.J., Lister, P.D., Mechanisms of beta-lactam resistance among Pseudomonas aeruginosa. Curr Pharm Des 19 (2013), 209–222.
264. Wood, T.K., Knabel, S.J., Kwan, B.W., Bacterial persister cell formation and dormancy. Appl Environ Microbiol 79 (2013), 7116–7121.
265. Wright, G.D., Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv Drug Deliv Rev 57 (2005), 1451–1470.
266. Wright, A., Hawkins, C.H., Anggard, E.E., Harper, D.R., A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34 (2009), 349–357.
267. Yan, J.J., Hsueh, P.R., Lu, J.J., Chang, F.Y., Ko, W.C., Wu, J.J., Characterization of acquired beta-lactamases and their genetic support in multidrug-resistant Pseudomonas aeruginosa isolates in Taiwan: the prevalence of unusual integrons. J Antimicrob Chemother 58 (2006), 530–536.
268. Yang, F., Gu, J., Yang, L., Gao, C., Jing, H., et al. Protective efficacy of the Trivalent Pseudomonas aeruginosa vaccine candidate PcrV-OprI-Hcp1 in Murine Pneumonia and burn models. Sci Rep, 7, 2017, 3957.
269. Yang, L., Nilsson, M., Gjermansen, M., Givskov, M., Tolker-Nielsen, T., Pyoverdine and PQS mediated subpopulation interactions involved in Pseudomonas aeruginosa biofilm formation. Mol Microbiol 74 (2009), 1380–1392.
270. Yildirimer, L., Thanh, N.T., Loizidou, M., Seifalian, A.M., Toxicology and clinical potential of nanoparticles. Nano Today 6 (2011), 585–607.
271. Zavascki, A.P., Goldani, L.Z., Li, J., Nation, R.L., Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60 (2007), 1206–1215.
272. Zhang, L., Hinz, A.J., Nadeau, J.P., Mah, T.F., Pseudomonas aeruginosa tssC1 links type VI secretion and biofilm-specific antibiotic resistance. J Bacteriol 193 (2011), 5510–5513.
273. Zhang, L., Mah, T.F., Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J Bacteriol 190 (2008), 4447–4452.
274. Zheng, Z., Tharmalingam, N., Liu, Q., Jayamani, E., Kim, W., et al. Synergistic efficacy of Aedes aegypti antimicrobial peptide Cecropin A2 and Tetracycline against Pseudomonas aeruginosa. Antimicrob Agents Chemother, 61, 2017.
275. Zhou, Y., Peng, Y., Synergistic effect of clinically used antibiotics and peptide antibiotics against Gram-positive and Gram-negative bacteria. Exp Ther Med 6 (2013), 1000–1004.
276. Zhu, X., Shan, A., Ma, Z., Xu, W., Wang, J., et al. Bactericidal efficiency and modes of action of the novel antimicrobial peptide T9W against Pseudomonas aeruginosa. Antimicrob Agents Chemother 59 (2015), 3008–3017.